Participants who were diagnosed with Stage I-III colorectal cancer will undergo testing with mt-sDNA followed by a questionnaire about satisfaction with mt-sDNA (multitarget stool DNA panel), prior to their scheduled colonoscopies at years 1 and 4 after diagnosis.
Participants will be asked to provide a stool sample for mt-sDNA (Cologuard) testing that will be collected within 90 days before their scheduled colonoscopy. The kit will be given to the participant by study personnel and mailed back directly to Exact Science.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of stage I, II or III adenocarcinoma of the colon or rectum
Receipt of preoperative colonoscopy
Receipt of bowel resection; use of adjuvant chemotherapy or radiation therapy as clinically indicated
You may not be if
Stage IV colorectal cancer
Surgical treatment with subtotal colectomy or total proctocolectomy
Diagnosis of inflammatory bowel disease (ulcerative colitis or Crohn's disease)
Diagnosis of polyposis syndrome including Lynch syndrome or familial polyposis
Presence of advanced adenomas (1 cm or larger, villous features and/or high grade dysplasia) that were not removed at the preoperative colonoscopy or contained in the resection specimen.
Inability to provide informed consent
Inability to understand spoken and written English
Medical comorbidities that would be contraindications to sedation or that would preclude any benefit of routine surveillance post-resection. These would be at the discretion of the participant's providers.
Clareo Health | The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors
